BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32012858)

  • 21. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
    Stahl A; Mueller BM
    Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.
    Ahmed N; Oliva K; Wang Y; Quinn M; Rice G
    Proteomics; 2003 Mar; 3(3):288-98. PubMed ID: 12627382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
    Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
    Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
    García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
    Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
    Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
    Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.
    Hau AM; Leivo MZ; Gilder AS; Hu JJ; Gonias SL; Hansel DE
    Cell Signal; 2017 Jan; 29():96-106. PubMed ID: 27777073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
    Besch R; Berking C; Kammerbauer C; Degitz K
    Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.
    Raghu H; Lakka SS; Gondi CS; Mohanam S; Dinh DH; Gujrati M; Rao JS
    PLoS One; 2010 Aug; 5(8):e12458. PubMed ID: 20805979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of tumor growth by β-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model.
    Shi H; Liu L; Liu LM; Geng J; Chen L
    Melanoma Res; 2015 Feb; 25(1):15-21. PubMed ID: 25405459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
    Tucker TA; Dean C; Komissarov AA; Koenig K; Mazar AP; Pendurthi U; Allen T; Idell S
    Am J Respir Cell Mol Biol; 2010 Jun; 42(6):685-96. PubMed ID: 19635932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition.
    Jacobsen B; Ploug M
    Curr Med Chem; 2008; 15(25):2559-73. PubMed ID: 18855679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells.
    Baek MK; Park JS; Park JH; Kim MH; Kim HD; Bae WK; Chung IJ; Shin BA; Jung YD
    Cancer Lett; 2010 Apr; 290(1):123-8. PubMed ID: 19782465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic remodeling precedes mitochondrial outer membrane permeabilization in human glioma xenograft cells.
    Ponnala S; Chetty C; Veeravalli KK; Dinh DH; Klopfenstein JD; Rao JS
    Int J Oncol; 2012 Feb; 40(2):509-18. PubMed ID: 22076676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
    Cunningham O; Campion S; Perry VH; Murray C; Sidenius N; Docagne F; Cunningham C
    Glia; 2009 Dec; 57(16):1802-14. PubMed ID: 19459212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
    BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
    Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
    Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
    Kiyan J; Smith G; Haller H; Dumler I
    Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.